FIA
PHAT icon

FNY Investment Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

FNY Investment Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000
Closed -$51K – 781
2024
Q2 		$51K Hold
5,000
– – 0.03% 242
2024
Q1 		$53 Buy
+5,000
New +$42.5K 0.03% 257

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FNY Investment Advisers's PHAT Position: Q3 2024 in Review

FNY Investment Advisers sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 5,000 shares — an estimated $51K sold.

FNY Investment Advisers first reported a position in PHAT in Q1 2024 and held it in 2 quarters. The position peaked at $51K in Q2 2024. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • FNY Investment Advisers reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 5,000 Phathom Pharmaceuticals shares in Q3 2024, an estimated $51K.
  • FNY Investment Advisers first reported a position in Phathom Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • FNY Investment Advisers's Phathom Pharmaceuticals position peaked at $51K in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on FNY Investment Advisers's 13F filing for Q3 2024, filed 18 Oct 2024.